Ximbio

Home
Organisations
Cancer Research Horizons

Cancer Research Horizons

12 inventions

Anti-IFITM1, Polyclonal [IFITM1]

Invented at Cancer Research Horizons

Antigen/Gene or Protein Targets: Interferon-induced transmembrane protein 1

0 reviews 2 references 1 supplier

Anti-IFITM3, Polyclonal [IFITM3]

Invented at Cancer Research Horizons

Antigen/Gene or Protein Targets: Interferon-induced Transmembrane protein 3

0 reviews Add a reference 1 supplier

Anti-BarX2 [BAR X2 8A7/1]

Invented at Cancer Research Horizons

ELISA IHC IF WB

Antigen/Gene or Protein Targets: BarX2

0 reviews Add a reference 1 supplier

Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound)

Invented by Dr Mark Charles at Cancer Research Horizons

Antigen/Gene or Protein Targets: Protein Kinase D (PKD)

0 reviews 14 references 1 supplier

LIMK inhibitor CRT0105950 Small Molecule (Tool Compound)

Invented by Dr Mark Charles at Cancer Research Horizons

Antigen/Gene or Protein Targets: LIMK1 and LIMK2

0 reviews 2 references 1 supplier

AKR1C3 inhibitor CRT0036521 Small Molecule (Tool Compound)

Invented by Dr Laurent Rigoreau at Cancer Research Horizons

Antigen/Gene or Protein Targets: AKR1C3

0 reviews 2 references 1 supplier

AKR1C3 inhibitor CRT0083914 Small Molecule (Tool Compound)

Invented by Dr Laurent Rigoreau at Cancer Research Horizons

Antigen/Gene or Protein Targets: AKR1C3

0 reviews 2 references 1 supplier

AKR1C3 inhibitor CRT0093964 Small Molecule (Tool Compound)

Invented by Dr Laurent Rigoreau at Cancer Research Horizons

Antigen/Gene or Protein Targets: Type 5 17-β-Hydroxysteroid Dehydrogenase (AKR1C3)

0 reviews 2 references 1 supplier

Protein Kinase D inhibitor CRT5 (CRT0066051) Small Molecule (Tool Compound)

Invented by Dr Mark Charles at Cancer Research Horizons

Antigen/Gene or Protein Targets: Protein Kinase D (PDK)

0 reviews 4 references 1 supplier

Anti-nNav 1.5 [4G8:1G7]

Invented at Cancer Research Horizons

FACS IHC IF WB

Antigen/Gene or Protein Targets: Neonatal Nav1.5 (Voltage gated Sodium Channel Nav1.5)

0 reviews 5 references 1 supplier

Page 1 of 2

Next Last

61 reagents managed

Anti-MBP [R29.6]

Invented by Julian Gannon at Cancer Research UK London Research Institute: Clare Hall Laboratories

$Adapted from Verhoeven et al. 2009. PLoS One. 4(8):e6739. PMID: 19707582 The 17 kDa OmpA degradation band fractionates to the soluble periplasmic fraction. Soluble periplasmic fractions (s) and insoluble cell pellet (i) were prepared as described in Supplementary Materials and Methods. Shown are immunoblots of the strain MC1061ΔOmpA containing constructs expressing full-length OmpA without tag insertion (pGI9) and full length OmpA with a 3xFLAG inserted in Loop 2 (pGV32). The latter protein is present at the expected height in the insoluble fraction, as expected for a properly assembled OM protein. The stronger 17 kDa degradation band is present in the soluble periplasmic fraction instead. Only the relevant portions of the blot are shown. The soluble periplasmic protein MBP (40 kDa), inducible by growth on maltose (0.2%), was used as a fractionation marker. The polyclonal anti-OmpA antibody was used in a 1∶10000 dilution (upper blot) and the monoclonal anti-MBP antibody (Abcam, #ab65) was used at a concentration of 1.8 µg/ml (lower blot).$